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Using a decision-analytic model, we evaluated the effectiveness and cost-effectiveness of surveillance for hepatocellular carcinoma
(HCC) in individuals with cirrhosis. Separate cohorts with cirrhosis due to alcoholic liver disease, hepatitis B and hepatitis C were
simulated. Results were also combined to approximate a mixed aetiology population. Comparisons were made between a variety of
surveillance algorithms using a-foetoprotein (AFP) assay and/or ultrasound at 6- and 12-monthly intervals. Parameter estimates were
obtained from comprehensive literature reviews. Uncertainty was explored using one-way and probabilistic sensitivity analyses. In the
mixed aetiology cohort, 6-monthly AFPþ ultrasound was predicted to be the most effective strategy. The model estimates that,
compared with no surveillance, this strategy may triple the number of people with operable tumours at diagnosis and almost halve
the number of people who die from HCC. The cheapest strategy employed triage with annual AFP (incremental cost-effectiveness
ratio (ICER): d20 700 per quality-adjusted life-year (QALY) gained). At a willingness-to-pay threshold of d30 000 per QALY the most
cost-effective strategy used triage with 6-monthly AFP (ICER: d27 600 per QALY gained). The addition of ultrasound to this strategy
increased the ICER to d60 100 per QALY gained. Surveillance appears most cost-effective in individuals with hepatitis B-related
cirrhosis, potentially due to younger age at diagnosis of cirrhosis. Our results suggest that, in a UK NHS context, surveillance of
individuals with cirrhosis for HCC should be considered effective and cost-effective. The economic efficiency of different surveillance
strategies is predicted to vary markedly according to cirrhosis aetiology.
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Hepatocellular carcinoma (HCC) occurs mainly in cases of
cirrhosis, which, in turn, tend to be secondary to either alcoholic
liver disease (ALD) or infection with hepatitis B or C viruses
(HBVs/HCVs). Symptomatic HCC typically presents late with a
bleak prognosis, whereas HCCs detected during formal surveil-
lance are smaller, more likely to be uninodular and more
commonly amenable to curative treatment (De Masi et al, 2005).
For this reason, UK (Ryder, 2003), European (Bruix et al, 2001)
and American (Bruix and Sherman, 2005) clinical guidelines
recommend routine surveillance for HCC among individuals with
cirrhosis, and approximately three-quarters of UK gastroenterolo-
gists undertake such a programme, mostly using a combination of
periodic serum a-foetoprotein (AFP) testing and ultrasound (US)
(Lai et al, 2002).
However, consensus has not been reached as to the optimal
surveillance strategy. We therefore developed a decision-analytic
model to assess the effectiveness and cost-effectiveness of a range
of different surveillance strategies in the United Kingdom. We
considered populations with cirrhosis secondary to HBV or HCV
infection, and as a result of ALD.
MATERIALS AND METHODS
Overview of model
We developed a state-transition (Markov) model using TreeAge
Prot 2005 (TreeAge Software, Williamstown, MA, USA) to
compare alternative surveillance strategies. In this approach,
disease progression is modelled as movement between different
health states over time. Time is modelled as a series of fixed cycles,
in this case 1 month, with probabilities of movement between
states calculated per cycle. Costs and utility values are attached to
each state, and the differences between the aggregated costs and
health outcomes in each simulation are used to estimate the cost-
effectiveness of surveillance, expressed as incremental cost per
quality-adjusted life-year (QALY) (Sonnenberg and Beck, 1993).
Costs and QALYs were discounted at 3.5% per year (HM Treasury,
2003). The perspective of the analysis is that of the UK NHS.
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Simulated populations
The population of interest is people with compensated cirrhosis
aged 70 years or less with no pre-existing medical conditions that
might preclude treatment with liver transplantation (OLT) or
hepatic resection (including current alcohol or intravenous drug
use). The model considers three cirrhosis aetiologies (ALD, HBV
and HCV). Results were also combined to simulate a mixed
aetiology cohort, consisting of the following proportions (based on
an average of estimates provided by gastroenterologists in several
centres around the United Kingdom): 57.6% ALD, 7.3% HBV and
35.1% HCV.
Model structure
The structure of the model is shown in Figure 1. For the natural
history component of the model, we defined three classes of HCC:
small (o2 cm in diameter), medium (2–5 cm) and large (45 cm).
Tumour characteristics in terms of detectability and treatability
are reflected in the transition probabilities. The following
simplifying assumptions were made: (i) progression from
cirrhosis to decompensated cirrhosis is irreversible; (ii) the rate
of incidence of HCC is the same in compensated and decom-
pensated livers; (iii) tumour diameter is used as a surrogate index
of all characteristics of tumour progression (multifocal tumours
are not modelled separately, since tumour nodularity is hetero-
geneous in the populations from which parameters have
been drawn; therefore, what our model defines as ‘medium’
tumours would, in real-world practice, include those with
multiple, small nodules that would not preclude transplantation,
and a ‘large’ tumour may be thought to include those which are
diffuse in nature); (iv) the presence of an HCC is only associated
with additional mortality risk when it becomes ‘large’ (at which
point it is also very likely to become symptomatic) and (v)
compensated cirrhosis is not subject to an excess mortality rate, as
the primary causes of death in these individuals are those already
accounted for in the model (i.e., progression to decompensation
and/or HCC).
The surveillance programme is superimposed onto the disease
process. We simulated six different surveillance regimes, consist-
ing of AFP-led, US-led and combined screening at 6- or 12-
monthly intervals (Figure 2). These were based on European
guidelines, which recommend that the diagnosis of HCC be based
on two coincident imaging techniques (Bruix et al, 2001). For
comparison, we also modelled an arm simulating no surveillance.
The possibility of incidental/symptomatic presentation of HCC is
modelled at all stages of disease. All confirmatory imaging is by CT
scan. We assumed 100% compliance with the surveillance
programme in the base-case analysis.
We modelled a mixed treatment approach using OLT and
resection. People can enter the OLT waiting list following diagnosis
of either a surgically treatable HCC or decompensated cirrhosis.
Each person is as likely to receive a liver as any other, regardless of
the reason for listing. While on the waiting list, people are subject
to the same natural history process as those prelisting, and no
‘bridging’ therapies are simulated. People who undergo successful
surgical treatment enter a simplified disease process in which
excess mortality rates and associated costs and utilities encompass
the spectrum of possible post-treatment experiences. There is no
waiting list for liver resection. Some people are deemed unsuitable
for either surgical treatment. A proportion of people with
surgically untreatable small and medium-sized tumours receive
palliative treatment with radiofrequency ablation and percuta-
neous ethanol injection. On progression to ‘terminal HCC large’,
an excess mortality with associated costs and utilities is applied
that reflects the palliation provided by transarterial chemoembo-
lisation for a proportion of people.
Parameters
Model parameters are listed in Tables 1 –3. Estimates were
obtained from literature searches in a range of electronic databases
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Figure 1 Influence diagram illustrating the natural history and treatment pathways simulated in the model.
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Figure 2 Decision trees illustrating the three screening algorithms investigated in the model.
Table 1 Model parameters: transition probabilities defining natural history, surveillance and therapy
Range
Parameter Cohort Value Source Lower Upper
Starting age of cohort (mean years at diagnosis) ALD 53.3 Roberts et al (2005) 43.3 63.3
HBV 44.0 Fattovich et al (1995) 34.0 54.0
HCV 54.0 Fattovich et al (1997) 44.0 64.0
Gender of cohort (% male) ALD 70.1 ONS mortality statistics 50.0 90.2
HBV 86.5 Fattovich et al (1995) 82.6 89.7
HCV 58.1 Fattovich et al (1997) 53.1 62.9
Upper age limit for surveillance 70 Authors’ assumption 60 80
Incidence of decompensation (% per year) ALD 3.3 Assumed as for HBV 1.8 7.0
HBV 3.3 Fattovich et al (2002) 1.8 6.0
HCV 5.3 Fattovich et al (2002) 3.9 7.0
Incidence of HCC (% per year) ALD 1.7
)
Fattovich et al (2004) 1.2 2.2
HBV 2.2 1.6 2.8
HCV 3.7 3.2 4.2
Tumour growth rate (volume doubling time) (days) 127a Taouli et al (2005) 80b 203c
Proportion diagnosed with HCCS assigned to resection/OLT/palliative care 20:75:5 Authors’ assumption 10:85:5 30:65:5
Proportion diagnosed with HCCM assigned to resection/OLT/palliative care 5:85:10 Authors’ assumption 2:88:10 10:80:10
Median days on OLT waiting listd 72e UK Transplant 68f 76g
Excess mortality due to compensated cirrhosis (% per annum) 0 Authors’ assumption 0 5
Excess mortality due to decompensated cirrhosis (% per annum) ALD 17.7 h 12.7 32.5
HBV 22.5 Fattovich et al (2002) 18.9 32.5
HCV 12.9 Fattovich et al (1997) 12.7 14.0
Survival rate following OLT (% at 90 days/1 year/5 years) ALD 94:92:55
9=
;
UK Transplant 87:85:38 100:100:71
HBV 85:78:69 97:66:54 95:90:83
HCV 93:88:86 88:82:41 97:93:71
Survival rate following resection (% at 90 days/1 year/3 years/5 years) 96:85:62:51 Llovet et al (1999) 89:79:54:36 99:88:76:58
Excess mortality associated with occult HCCL (% per year) 72.9 Greten et al (2005) 34.6 97.3
Excess mortality associated with known HCCL (% per year) 64.4
i 33.6 84.8
Background (all-cause) mortality j Government Actuary’s
Department (2006)
— —
Probability of AFP o20 ng ml1/20–400 ng ml1/4400 ng ml1
In HCCS 0.352:0.568:0.080
)
Pooled IPDk 0.261:0.464:0.039 0.456:0.667:0.155
In HCCM 0.378:0.500:0.122 0.276:0.389:0.065 0.492:0.611:0.215
In HCCL 0.222:0.444:0.334 0.063:0.189:0.121 0.547:0.733:0.646
With no HCC 0.906:0.088:0.006 Trevisani et al (2001) 0.853:0.054:0.001 0.941:0.140:0.033
Cost–utility of surveillance for HCC
J Thompson Coon et al
1168
British Journal of Cancer (2008) 98(7), 1166 – 1175 & 2008 Cancer Research UK
C
lin
ic
a
l
S
tu
d
ie
s
(full details and strategies available from the authors). We sought
data that fulfilled the following criteria: large, recent studies of
UK patients with a diagnosis of cirrhosis (with details of
aetiology). For parameters in which there were no UK-based
studies available, we sought data from countries with a similar
disease profile. Cost data were obtained from national (UK NHS;
Department of Health (DoH), 2005) sources where available,
supplemented by data from a recent UK-based observational study
of patients with HCV (Wright et al, 2006). Historical values were
inflated to 2004 prices.
Analysis of uncertainty
Extensive one-way sensitivity analyses were undertaken to
explore, which of the input parameters had the greatest impact
on results. For simplicity, these were performed using a single-core
comparison: 6-monthly AFPþUS vs no surveillance. Owing
to the paucity of reliable estimates for US sensitivity and the
possibility that these estimates do not accurately reflect
current practice, we examined the impact of simultaneously
varying the sensitivity of US for detecting tumours over a range
of correlated values from 5 to 50, 10 to 75 and 50 to 100% for small,
medium and large tumours, respectively. We also performed
scenario analyses testing less optimistic assumptions about patient
compliance.
Probabilistic sensitivity analysis was also undertaken. Ten
thousand Monte Carlo simulations per aetiology were run, with
key input values randomly drawn from probabilistic density
functions in each iteration. Distributions can be obtained from the
authors.
RESULTS
Effectiveness of surveillance
Table 4 summarises the effectiveness of each surveillance strategy
in the mixed aetiology cohort. The 6-monthly AFPþUS was most
effective across all outcomes, more than tripling the number of
HCCs diagnosed while operable, and almost halving the number
dying from HCC, when compared with no surveillance. However,
the cheapest strategy, annual AFP-triage, still achieved substantial
gains: for example, more than doubling the number of operable
HCC found and increasing the number of small tumours found
more than six-fold.
Cost– utility of surveillance
Cost– utility results are shown in Table 5. In an incremental
analysis, neither of the US-only strategies would be considered
(since they are both slightly less effective and more costly than
surveillance at the same frequency with AFP-triage). Therefore, in
the mixed aetiology cohort the cheapest surveillance strategy is
annual AFP-triage, with incremental cost-utility of d20 700 per
QALY. Doubling the frequency of surveillance would increase the
mean number of QALYs by 0.035 at a cost of d1000 each, giving an
incremental cost-effectiveness ratio (ICER) of d27 000 per QALY
gained.
Deterministic sensitivity analyses
The cost– utility estimates appear to be most sensitive to changes
in tumour growth rate, mortality following OLT and excess
Table 1 (Continued )
Range
Parameter Cohort Value Source Lower Upper
Probability of detection by US
HCCS 0.107
9>=
>;
Bennett et al (2002) 0.037 0.272
HCCM 0.286 0.082 0.641
HCCL 0.750 0.301 0.954
False-positive rate for US 3.5% 1.6% 7.4%
Probability of detection by CT
HCCS 1.000
)
Authors’ assumptionl 0.605m —
HCCM 1.000 0.903
n —
HCCL 1.000 0.950
o —
False-positive rate for CT 10.2% Brancatelli et al (2003) 7.6% 13.7%
Annual symptomatic/incidental presentation rate
HCCS 1.6%
9=
;
Rates calibrated to reflect
tumour sizes reported by
Trevisani et al (2002)
0% 16.2%
HCCM 12.1% 0% 30.3%
HCCL 50.0% 0% 100%
AFP¼ a-foetoprotein; ALD¼ alcoholic liver disease; CT¼ computed tomography; HBV; hepatitis B virus; HCC¼ hepatocellular carcinoma; HCCL¼ large hepatocellular
carcinoma; HCCM¼medium hepatocellular carcinoma; HCCS¼ small hepatocellular carcinoma; HCV¼ hepatitis C virus; IPD¼ individual patient data; OLT¼ orthotopic liver
transplantation; ONS¼Office of National Statistics; US¼ ultrasound. aEquivalent to a monthly probability of progression from HCCS to HCCM¼ 0.056; HCCM to
HCCL¼ 0.036. bEquivalent to a monthly probability of progression from HCCS to HCCM¼ 0.036; HCCM to HCCL¼ 0.023. cEquivalent to a monthly probability of progression
from HCCS to HCCM¼ 0.089; HCCM to HCCL¼ 0.056. dAll individuals have the same probability of receiving a transplant, regardless of reason for listing. eEquivalent to a
monthly probability of receiving a transplant¼ 0.254. fEquivalent to a monthly probability of receiving a transplant¼ 0.242. gEquivalent to a monthly probability of receiving a
transplant¼ 0.267. hAverage of HBV and HCV values in the absence of a reliable ALD-specific estimate. iAssuming 33% of patients receive TACE. jVariable age- and sex-specific
rates, increasing as the cohort ages. kPooled from individual patient data reported in six separate series (Sheu et al, 1985; Ebara et al, 1986; Cottone et al, 1988; Oka et al, 1990;
Cottone et al, 1994; Zoli et al, 1996). lBecause, in the algorithm simulated by the model, the use of CT is limited to a second line, confirmatory context, our base-case assumption
was that all such scans would accurately identify HCC, where present. Although CT is subject to a significant false-negative rate when used in blinded, first-line assessments
(Taouli et al, 2004; Baron and Brancatelli, 2004), we made the assumption that such fallibility should not be apparent in this context. The impact of this assumption was tested in
sensitivity analyses. mSource: Valls et al (2004). nSource: Spreafico et al (1997). oAuthors’ assumption, in the absence of suitable published data source. On the basis of the
rationale that sensitivity should be greater than the evidence-based figure adopted for HCCM, but less than 100%.
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mortality associated with undiagnosed large tumours. Quality of
life in compensated cirrhosis and following OLT are also
important, as are costs associated with US and OLT. When the
cirrhosis aetiologies are considered separately, the mean age at
diagnosis in individuals with HBV-related cirrhosis becomes an
important variable.
Increases in US sensitivity lead to improved effectiveness in all
surveillance strategies. At both annual and 6-monthly frequencies,
US-led surveillance becomes more effective than AFP-triage surveil-
lance when it can be assumed that US is at least sensitive enough to
detect one in five small tumours, one in three medium tumours and
two in three large tumours. However, when costs are also considered,
it is only in the HBV cohort that US becomes more cost-effective than
AFP-triage surveillance at the same frequencies.
When we examined imperfect patient compliance with surveil-
lance, we found a noticeable reduction in effectiveness. However,
there was a commensurate reduction in costs, so incremental cost-
effectiveness results were not greatly altered.
Table 2 Model parameters: costs
Range
Parameter Value Source(s) Lower Upper
Unit costs
AFP test d4 Each Local dataa and Wright et al (2006)b d2 d8
CT scan d110 Each
)
(NSRC (2004)) and Wright et al (2006)b d50 d130
Ultrasound scan d50 Each d26 d100
MRI scan d200 Each d180 d400
Outpatient appointment d101 Each Department of Health
NSRC (2004)
d72 d133
PEI d381 Each
)
Wright et al (2006) d190 d762
RFA d754 Each d377 d1508
TACE d537 Each d268 d1074
State costs
All compensated cirrhosis states d1171 Per annum
)
Wright et al (2006) d718 d1624
All decompensated cirrhosis states d9385 Per annum d6407 d12 363
All known HCC states d1230 Extrac per annum d615 d2460
OLT d21 800 Each NSRC (2004) d16 700 d31 800
Post-OLT (year 1) d9872 Per annum

Department of Health (DoH) (2005) studyd d4831 d14 921
Post-OLT (year 2) d1564 Per annum d821 d2315
Resection d5400 Each NSRC (2004) d1500 d6000
Post resection d3532 Per annum Authors’ assumptione d2338 d4763
Palliative care (HCCS and HCCM) d1619 Extra
f per annum Authors’ assumptiong d809 d3237
Palliative care (HCCL) d177 Extra
f per annum Authors’ assumptionh d88 d354
Event costs
False positive d512 Each Authors’ assumptioni d374 d796
Symptomatic/incidental diagnosis d164 Each Authors’ assumptionj d78 d238
AFP¼ a-foetoprotein; CT¼ computed tomography; HCC¼ hepatocellular carcinoma; HCCL¼ large hepatocellular carcinoma; HCCM¼medium hepatocellular carcinoma;
HCCS¼ small hepatocellular carcinoma; MRI¼magnetic resonance imaging; OLT¼ orthotopic liver transplantation; PEI¼ percutaneous ethanol injection; RFA¼ radiogrequency
ablation; TACE¼ transarterial chemoembolisation. aValues obtained by the authors from a small sample of NHS Trust Clinical Biochemistry Departments. bValues used represent
an average of the available data points (rounded to prevent spurious appearance of precision), with the broad spread of plausible values explored in sensitivity analysis. cIn
addition to costs of underlying cirrhosis. dData collected by Longworth et al (2001), as re-analysed by Wright et al (2006). eAssumed to be the same as the annual cost for a
weighted mix of compensated and decompensated cirrhosis, plus an amount to reflect HCC recurrence (at a rate of 70% by 5 years) and treatment (33% OLT; 33% repeat
resection; 33% palliative treatments). fIn addition to costs of underlying cirrhosis and costs of HCC. gAssuming 33% of patients receive RFA on an average of once per year; and
33% of patients receive PEI on an average of six times per year. hAssuming 33% of patients receive TACE on an average of once per year. iAssumes that the discovery of a false-
positive diagnosis would involve one additional CT scan, one additional MRI scan and two additional outpatient visits. jAssumes that confirming a symptomatic or incidental HCC
diagnosis would entail one AFP test, one liver ultrasound and one CT.
Table 3 Model parameters: utility values
Range
Health state Markov states in which applied Value Source Lower Upper
Compensated cirrhosis All compensated cirrhosis states (±known or occult HCCS
or HCCM, including patients on the OLT waiting list)
0.75 Chong et al (2003) 0.66 0.83
Decompensated cirrhosis All decompensated cirrhosis states (±known or occult HCCS or HCCM,
including patients on the OLT waiting list)
0.66 Chong et al (2003) 0.46 0.86
HCC Terminal HCCL 0.64 Chong et al (2003) 0.44 0.86
Month of OLT OLT (month of) 0.50 Authors’ assumption 0.30 0.60
Post-OLT (year 1) Post-OLT (year 1) 0.69 Ratcliffe et al (2002) 0.64 0.74
Post-OLT (year 2+) Post-OLT (year 2 onwards) 0.73 Ratcliffe et al (2002) 0.67 0.78
Resection Resection (month of) 0.50 Authors’ assumption 0.30 0.60
Post resection Post resection 0.73 a 0.62 0.84
HCC¼ hepatocellular carcinoma; HCCL¼ large hepatocellular carcinoma; HCCM¼medium hepatocellular carcinoma; HCCS¼ small hepatocellular carcinoma; OLT¼ orthoto-
pic liver transplantation. aWeighted average of the values adopted for compensated and decompensated cirrhosis.
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The model is extremely sensitive to the discount rate
applied (3.5% per year for both costs and utilities in the base
case). The ICER for 6-monthly AFPþUS compared with no
surveillance ranges from d19 400 per QALY if no discounting is
applied to d35 800 per QALY if rates of 6% are used for both costs
and utilities.
Probabilistic sensitivity analysis
Figure 3 shows cost-effectiveness acceptability curves (Fenwick
et al, 2001; Fenwick et al, 2004) for ALD, HBV, HCV and the mixed
cohort. These graphs show the probability that each strategy would
be considered the most cost-effective (in terms of highest net
Table 4 Lifetime effectiveness of surveillance
No
surveillance
Annual
AFP-triage
Annual
US
Annual
AFP+US
6-monthly
AFP-triage
6-monthly
US
6-monthly
AFP+US
% with operable HCC 5.1% 11.9% 11.7% 13.5% 15.3% 15.0% 16.9%
% HCCS at diagnosis 0.3% 1.9% 1.5% 2.3% 3.1% 2.6% 3.7%
% HCCM at diagnosis 2.1% 3.8% 4.1% 4.2% 4.2% 4.6% 4.4%
% getting OLTs 17.1% 19.1% 19.1% 19.2% 20.1% 20.0% 20.3%
% OLTs for known HCC 8.3% 20.3% 20.0% 23.2% 25.3% 24.9% 27.9%
% dying of HCC 19.9% 14.7% 14.9% 13.5% 12.0% 12.3% 10.8%
NNS to prevent 1 deatha — 19 20 15 13 13 11
% dead by age 75 years 69.3% 68.4% 68.5% 68.2% 68.0% 68.0% 67.8%
NNS to prevent 1 deathb — 114 117 93 78 79 68
HCC¼ hepatocellular carcinoma; HCCL¼ large hepatocellular carcinoma; HCCM¼medium hepatocellular carcinoma; HCCS¼ small hepatocellular carcinoma; NNS¼ number
needed to be under surveillance; OLT¼ orthotopic liver transplantation. aNNS to prevent one death from HCC. bNNS to prevent one ‘premature’ death (age o75 years).
Table 5 Cost–utility analyses
Incremental analysis
Strategy Cost (d) Utility (QALYs) Cost (d) Utility (QALYs) d/QALY (ICER)
ALD
No surveillance d26 100 9.359
Annual AFP-triage d27 400 9.410 d1300 0.051 d24 800
Annual US d27 700 9.410 Extendedly dominated
Annual AFP+US d28 100 9.422 Extendedly dominated
6-monthly AFP-triage d28 200 9.433 d800 0.024 d35 500
6-monthly US d28 800 9.434 Extendedly dominated
6-monthly AFP+US d29 200 9.445 d1000 0.011 d88 000
HBV
No surveillance d29 600 10.858
Annual AFP-triage d31 700 11.069 d2100 0.211 d10 200
Annual US d32 100 11.066 Dominated
Annual AFP+US d32 700 11.119 Extendedly dominated
6-monthly AFP-triage d33 000 11.168 d1300 0.099 d12 700
6-monthly US d33 600 11.164 Dominated
6-monthly AFP+US d34 200 11.216 d1300 0.048 d26 800
HCV
No surveillance d27 600 8.087
Annual AFP-triage d29 500 8.172 d1900 0.085 d22 200
Annual US d29 700 8.172 Extendedly dominated
Annual AFP+US d30 300 8.193 Extendedly dominated
6-monthly AFP-triage d30 600 8.212 d1100 0.040 d27 600
6-monthly US d31 000 8.213 Extendedly dominated
6-monthly AFP+US d31 600 8.232 d1000 0.020 d50 400
Mixed aetiology
No surveillance d26 900 9.021
Annual AFP-triage d28 400 9.096 d1500 0.075 d20 700
Annual US d28 800 9.096 Dominated
Annual AFP+US d29 200 9.114 Extendedly dominated
6-monthly AFP-triage d29 400 9.131 d1000 0.035 d27 600
6-monthly US d29 900 9.131 Dominated
6-monthly AFP+US d30 400 9.148 d1000 0.017 d60 100
AFP¼ a-foetoprotein; ALD¼ alcoholic liver disease; HBV; hepatitis B virus; HCV¼ hepatitis B virus; ICER¼ incremental cost-effectiveness ratio; QALY¼ quality-adjusted life-
year; US¼ ultrasound. Discount rate of 3.5% per annum applied to all costs and benefits.
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monetary benefit) at different levels of willingness to pay for a
QALY.
At a willingness-to-pay threshold of d30 000 per QALY, the most
intensive surveillance protocol simulated (6-monthly AFPþUS) is
only likely to be considered cost-effective in individuals with HBV-
related cirrhosis. In those with HCV-related cirrhosis, 6-monthly
AFP-triage is more likely to be considered cost-effective; indeed,
willingness to pay would have to rise to around d65 000 per QALY
before 6-monthly AFPþUS becomes most likely to be considered
cost-effective in this population. In individuals with ALD-related
cirrhosis, there is uncertainty about which strategy would be most
cost-effective at a willingness-to-pay threshold of d30 000 per
QALY, with no surveillance, annual AFP-triage and 6-monthly
AFP-triage having approximately equal likelihood of maximal
cost-effectiveness.
In the mixed aetiology cohort, which approximates the decision
framework if a single strategy is to be adopted across all
aetiologies, surveillance of any kind can only be recommended if
willingness to pay approaches d30 000 per QALY. At this level, 6-
monthly AFP-triage appears to be the most cost-effective
surveillance protocol, and remains the foremost option until
willingness to pay reaches very high levels. This analysis suggests
that society would have to be prepared to spend nearly d70 000 per
QALY gained before the most effective strategy – 6-monthly
AFPþUS – could confidently be assumed to provide best value for
money.
DISCUSSION
Summary of main findings
Our analysis suggests that, in patients with cirrhosis, surveillance
strategies for HCC are effective, and can often be considered cost-
effective. The most effective strategy for a mixed aetiology cohort
of individuals with cirrhosis is AFP assay combined with US
imaging on a 6-monthly basis. However, when costs are taken into
account, using AFP as a triage step may be preferable. Surveillance
is much more likely to be cost-effective in those with HBV-related
cirrhosis, while surveillance of people with ALD-related cirrhosis
appears least economically efficient.
Interpretation of findings
According to our simulation, the economic efficiency of different
surveillance strategies can be expected to vary substantially
according to cirrhosis aetiology. As a result, the most efficient
mode of resource allocation, from a purely decision-analytic
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Figure 3 Cost-effectiveness acceptability curves, showing relative probability of maximal cost-effectiveness among surveillance strategies. (A) ALD-related
cirrhosis; (B) HBV-related cirrhosis; (C) HCV-related cirrhosis; (D) mixed aetiology cohort (weighting: 57.6% ALD; 7.3% HBV; 35.1% HCV). Maximal cost-
effectiveness reflects the proportion of Monte Carlo simulations (10 000 per aetiology) in which each strategy generated the highest net monetary benefit.
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viewpoint, would be to offer surveillance of differing intensity to
each subgroup. However, apart from the practical complications of
establishing different recall pathways for different patient groups,
concerns might also be raised about the ethical implications of this
approach. For instance, one-way sensitivity analysis suggested that
the particularly good value offered in the HBV group may be
substantially due to the younger age of the cohort. By implication,
then, there may be further subgroups of individuals with HCV and
ALD, diagnosed with cirrhosis at a younger age, in which more
intensive surveillance might be particularly cost-effective.
Our results also suggest that reports of the AFP test’s demise
(Sherman, 2001) may be exaggerated, particularly if one adopts a
cost-effectiveness perspective. We believe one reason for this is
that previous authors may have failed to account fully for tumour
size in their analyses. Although the AFP test has been found to be
relatively insensitive for detecting HCC in general (Trevisani et al,
2001), it has the substantial advantage that its sensitivity is only
weakly correlated with tumour size, meaning that it should be a
valuable aid to the detection of some of the smallest, most easily
treated tumours. According to the evidence used in our model,
65% of tumours less than 2 cm in diameter secrete 20 ng ml1 or
more of AFP (although this figure may be an overestimate, with the
true proportion around 46%; Farinati et al, 2006). In contrast, our
model is configured to simulate US sensitivity of only 10.7% for
the smallest category of tumour (Bennett et al, 2002). Although this
is at the pessimistic end of the range of available evidence, it
should not be seen as an outlying estimate. Every study that has
used an optimal reference standard (explant pathology) to
investigate the diagnostic capabilities of US, in this setting, has
reported disappointing sensitivity for the tumours p2 cm in
diameter: 13.8% (Kim et al, 2001), 22.2% (Rode et al, 2001) and
30.0% (Liu et al, 2003). Even if one was to adopt the most positive
estimate available, all robust evidence suggests that US is less
sensitive than AFP assay for the detection of the smallest tumours.
Additionally, AFP is a very cheap test and, inevitably, this is a
crucial consideration from a cost-effectiveness perspective. The
fact that current guidelines do not recommend using AFP
screening may reflect the poor quality of current evidence or a
lack of explicit attention to cost-effectiveness considerations
during the development of clinical guidelines. However, a strategy
led by one single diagnostic modality will always run the risk of
serial false-negative findings, and this setting provides a good
example (some tumours never secrete AFP and will therefore never
be detected using an AFP-led approach and, equally, some
tumours will infiltrate diffusely and resist US detection).
Because tumour growth rate had a clear influence on cost-
effectiveness in the one-way sensitivity analysis, we investigated
this factor further. We performed stratified scenario analyses,
simulating three mixtures of slow-growing and fast-growing
tumours, instead of applying one average growth rate throughout
the model. While the combination of growth rates had an impact
on the effectiveness and cost-effectiveness of surveillance (the
more fast-growing HCCs, the more cost-effective surveillance
becomes), the incremental relationship between surveillance
strategies was preserved. The only practical implication of these
additional findings is to suggest that, if the true mix of HCCs
features a preponderance of slow-growing tumours, it may not be
cost-effective to offer any surveillance strategy at 6-monthly
intervals.
Strengths of the evaluation
This is the first analysis of the effectiveness and cost-effectiveness
of surveillance of cirrhosis for HCC in the UK NHS. Comprehen-
sive literature searches were conducted to inform the model
parameters, wherever possible choosing data either derived from
the UK population or most likely to be applicable to the UK
population.
Extensive exploration of model structures and uncertainty
suggest that our model more appropriately captures the disease
and surveillance process and impacts than previous studies in this
field. While we have assumed that decompensated cirrhosis is
irreversible, we showed in one-way sensitivity analysis that our
results are not greatly influenced by alterations in the annual rate
of progression from compensated to decompensated cirrhosis.
From this, it is safe to infer that allowing some regression from
decompensated back to compensated cirrhosis would not sig-
nificantly alter our main results. By accounting for the substantial
differences in age-related incidence, natural history and response
to treatment that exist according to cirrhosis aetiology, we
predict that different approaches to surveillance may be justified
according to different causes of cirrhosis.
Limitations of the evaluation
First, there is very little published evidence on which to base many
of the parameter estimates for the model, and few data originate
within the United Kingdom. This was particularly apparent for
defining US performance. Second, as the primary focus of this
evaluation was the effectiveness and cost-effectiveness of surveil-
lance, we have used a simplified approach to modelling treatment
in which OLT and resection are the only curative options available.
We performed limited modelling of nonsurgical/ablative therapies
as the evidence at the time of the analysis was inconclusive
(Di Bisceglie, 2005). Recent evidence, predominantly from Asia
(Izumi et al, 2007; Peng et al, 2007; Zytoon et al, 2007), suggests
that such therapies may improve survival in patients with small
tumours. If similarly promising findings could be shown in the
United Kingdom, we would expect widespread adoption of such
techniques to have beneficial cost-effectiveness implications, since
a minimally invasive approach is much cheaper than OLT, and
might also be expected to have less negative impact on quality of
life. Third, we have assumed that entry to the surveillance
programme is confined to those more likely to be considered
eligible for the available curative treatment options (OLT or
resection) and therefore assumes that high-risk activity (excessive
alcohol consumption, intravenous drug use and so on) has ceased,
and this may not be realistic. We have also assumed that the three
cirrhosis aetiologies are mutually exclusive and acknowledge that
many people develop cirrhosis as a result of multiple causes.
Comparison with other studies
There are no other studies published studies from Europe. We
identified three comparable studies from our literature searches
(Arguedas et al, 2003; Lin et al, 2004; Patel et al, 2005); all were
conducted in the United States and simulated HCV-related
cirrhosis only. In these studies, 6-monthly surveillance using
AFP and US produced utility gains of between 0.23 and 0.49
QALYs, compared with no surveillance, giving ICERs of between
$24 500 and $46 600 per QALY gained. Apart from obvious
dissimilarities in input values and assumptions – reflecting the
different populations and health-care systems simulated – there
are substantial differences in the structures of the models.
Crucially, ours is the only model to have accounted for tumour
size in simulating the sensitivity of surveillance.
Implications for future research
Further research is required in the following areas (i) further
modelling studies using alternative modelling methods such as
individual patient sampling techniques could be used to account
for heterogeneity in the patient population, so that factors such as
tumour growth rate, tumour characteristics and the variability in
individual patients’ serial test results could be assessed. Such
methods could also be used to assess the optimal surveillance
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strategy, the optimal surveillance interval and the effects of
surveillance on waiting lists for OLT; (ii) further modelling studies
could also investigate innovative surveillance strategies not
currently undertaken in clinical practice (e.g., alternating AFP
and US investigations at 6- or 12-monthly intervals, or measuring
change in AFP levels following serial tests rather than absolute
levels with fixed cutoff points); (iii) further empirical and
modelling analysis of the impact of age at diagnosis of cirrhosis
on the effectiveness and cost-effectiveness of surveillance; (iv)
empirical evaluation of newer imaging techniques (e.g., contrast-
enhanced US) to detect HCCs; and (v) assessment of the
effectiveness and cost-effectiveness of surveillance in other
aetiologies (e.g., nonalcoholic fatty liver disease) and using other
curative treatment options (e.g., ablative techniques).
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